102¦~1¤ë¸¹ ¹D ªk ªk °T (249)

DEEP & FAR

 

 

 

¬ü°ê±M§Q¥Ó½Ð¹ê°Èªº§ïÅÜ

 

 

ÁÂÃýÁn ±M§Q¤uµ{®v

¡P »²¤¯¤j¾Ç­¹«~¬ì¾Ç¨t

¡P ®ü¬v¤j¾Ç¥Íª«§Þ³N¬ã¨s©Ò

 

 

½Ðª`·N¬ü°ê±M§Q¥Ó½Ð¹ê°È©ó2012¦~9¤ë16¤é¦³©úÅ㪺§ïÅÜ¡C©ó¤U¦C¸ÑÄÀ±M§Q¥Ó½Ð®×´£¥X«Å»}®Ñ¡B·sªº®Ö­ã«á¬yµ{¤Î©ó¬ü°ê±M§Q°Ó¼Ð§½¶O¥Î©úÅã´£°ªªº§ïÅÜ¡G

«Å»}®Ñ¢w°£¤F®Ú¾Ú35 U.S.C. ¡± 371©Ò´£¥Xªº°ê®a¶¥¬q¥Ó½Ð®×(¡¥371¥Ó½Ð®×)¡A¦Ó½Ð¨D©ó2012¦~9¤ë16¤é«e©Ò¥Ó½Ð°ê»Ú¥Ó½Ð®×Àu¥ýÅv¤§¥~¡A2012¦~9¤ë15¤é¤§«á¥Ó½Ðªº©Ò¦³·s®×¡B©µÄò®×¤Î¤À³Î®×»Ý¨Ï¥Î·s¥Î»yªº«Å»}®Ñ¡C

¢w©ó2012¦~9¤ë16¤é«e´£¥X½Ð¨D°ê»Ú¥Ó½Ð®×Àu¥ýÅvªº¡¥371¥Ó½Ð®×ªº«Å»}®Ñ¥²¶·¨Ï¥Îªº«Å»}®Ñ¥Î»y¡C

¢w¬ü°ê±M§Q°Ó¼Ð§½¦b¨äºô­¶¤W¦³·s«Å»}®Ñªº½d¥»¡CµM¦Ó¡A¬ü°ê±M§Q°Ó¼Ð§½¤£·|´£¨Ñ«Å»}®Ñµ²¦X©e¥ô®Ñ¤Î«Å»}®Ñµ²¦XÅý´ç®Ñªºªí®æ¡C

¢w¬ü°ê±M§Q°Ó¼Ð§½¦b¨äºô­¶¤W¨Ã¥¼¦³·sªº°ê¥~»y¨¥ªº«Å»}®Ñªí®æ¡C

¢wÁöµM¬ü°ê±M§Q°Ó¼Ð§½ªºÅý´ç®Ñªº½d¥»¦³¤@­Óñ¦Wªº°Ï¶ô¡A¦ý¨C¦ìµo©ú¤H¤£»Ý­n¤À¶}ñ¸p«Å»}®Ñ¡C

¥Ó½Ð®×¸ê®Æªí(Application Data Sheets)¢w®Ú¾Ú35 U.S.C. ¡± 119¡B120¡B121©Î365¡A½Ð¨DÀu¥ýÅv©Î¨ü¯q©ó¤@­Ó«e®×®É¡A»Ý­n´£¥æ¥Ó½Ð®×¸ê®Æªí¡C

²Ä¤T¤è´£¥æ²{¦³§Þ³N¢w­Y¥ý«e§Þ³N¤§´£¥X¬°¥H¤U¸û¦­ªÌ¡G(a)±H°e®Ö­ã³qª¾ªº¤é´Á¡A©Î(b)¥H¤U¤§¸û«áªÌ(i)¥Ó½Ð®×¤½¶}¤é´Á¤§«áªº6­Ó¤ë¡A©Î(ii)²Ä¤@¦¸®Ö»é¤é¡A²Ä¤T¤è¥i´£¥æ¥ý«e§Þ³Nµ¹±M§Q§½¼fij¡C

¥Ó½Ð«á¬yµ{¢w³æ¤è´_¼f(Ex Parte Reexamination)¡B¸É¥R¼f¬d(Supplemental Examination)¡BÂù¤è¼f¬d(Inter-Partes Review)¤Î¹L´çªº°Ó·~¤èªk±M§Q±ÂÅv«á­«¼f(Transitional Business Method Patent Post Grant Review)¡C

³æ¤è´_¼f¢w¬ü°ê±M§Q°Ó¼Ð§½ªº³æ¤è´_¼f¶O¥Î¬°$17,750¡A¥]§t$4,320ªº©Úµ´½Ð¨D¶O¥Î¡C­Y½Ð¨D³Q©Úµ´¡A·|ÂkÁÙ$13,430¡C

¡]«ÝÄò¡^